Axinix5 mg

Axinix is a VEGFR-selective tyrosine kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC). Its use is classified by evidence strength as follows:

Established / Approved Uses

• Second-line monotherapy: Axinix is approved for advanced RCC after failure of one prior systemic therapy (e.g. a prior tyrosine kinase inhibitor or cytokine-based regimen). This is the core, best-established indication.
• First-line combination therapy: Axinix is also approved for first-line treatment of advanced RCC when given in combination with an immune checkpoint inhibitor (avelumab or pembrolizumab). Axinix is not used alone in this setting — combination with the checkpoint inhibitor is required for this indication.

Not Established

• Axinix is not approved and is not routinely recommended for cancers other than renal cell carcinoma; use outside RCC would be considered off-label and is uncommon.

Axinix is a specialist oncology medicine and must only be prescribed and monitored by, or in close consultation with, an oncologist.

Each film-coated tablet contains Axitinib as the active ingredient, commonly available in strengths of 1 mg, 3 mg, 5 mg, and 7 mg. Inactive ingredients typically include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and a film coating.

Axinix is an orally administered, small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By blocking these receptors, Axinix inhibits tumor angiogenesis (the formation of new blood vessels that tumors depend on for growth and spread), which slows tumor growth in renal cell carcinoma.

Axinix is supplied as film-coated oral tablets and is used exclusively under the supervision of a qualified oncologist as part of a structured cancer treatment plan.

Axinix belongs to the class of VEGFR-selective tyrosine kinase inhibitors (TKIs), a subclass of antineoplastic (anticancer) agents that act as angiogenesis inhibitors.

Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR-1, -2, -3). These receptors, when activated, drive angiogenesis and endothelial cell proliferation, processes that solid tumors, including renal cell carcinoma, rely on for growth, invasion, and metastasis.

By inhibiting VEGFR signaling, Axitinib reduces tumor vascularization, thereby limiting the tumor's oxygen and nutrient supply and slowing disease progression. Axitinib is extensively metabolized in the liver, predominantly by the CYP3A4/5 enzyme system, with minor contribution from CYP1A2, CYP2C19, and UGT1A1. It has a short elimination half-life of approximately 2.5 to 6.1 hours, which is why it is dosed twice daily.

Take Axinix tablets orally, whole, with water, with or without food, approximately 12 hours apart. Do not crush, chew, or split tablets. Take exactly as prescribed by the treating oncologist; do not change the dose or stop treatment without medical advice.

Strong CYP3A4/5 Inhibitors

Concomitant use of strong CYP3A4/5 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, indinavir, nefazodone, telithromycin, saquinavir) significantly increases Axinix plasma concentrations, raising the risk of toxicity. These should be avoided if possible; if concomitant use is unavoidable, the Axinix dose should be reduced by approximately half, with close monitoring for adverse effects.

Strong CYP3A4/5 Inducers

Concomitant use of strong CYP3A4/5 inducers (e.g. rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St. John's Wort) can significantly decrease Axinix plasma concentrations and reduce efficacy. A therapeutic alternative with no or minimal enzyme-inducing potential should be selected where possible; grapefruit and grapefruit juice should also be avoided.

Antihypertensive Agents

Axinix commonly causes hypertension; careful coordination with antihypertensive medications and blood pressure monitoring is required (see Precautions and Warnings).

Side effects of Axinix are common and require regular monitoring by the treating oncology team.

Very Common (≥20%)

• Diarrhea
• Fatigue and asthenia
• Hypertension
• Nausea and vomiting
• Decreased appetite and weight loss
• Dysphonia (hoarseness/voice changes)
• Hypothyroidism
• Palmar-plantar erythrodysesthesia (hand-foot syndrome)
• Rash and dry skin

Common but Less Frequent

• Stomatitis and mucosal inflammation
• Constipation, abdominal pain
• Headache
• Arthralgia
• Proteinuria

Serious (Uncommon but Important)

Arterial and venous thromboembolic events, hemorrhage, gastrointestinal perforation or fistula, hepatotoxicity, and reversible posterior leukoencephalopathy syndrome (RPLS) can occur — see Precautions and Warnings for details and required action.

Axinix may cause fetal harm based on its mechanism of action (VEGFR inhibition, which is essential to normal placental and fetal development). Axinix should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; women of reproductive potential should use effective contraception during treatment and for at least one week after the final dose, and should consult their physician immediately if pregnancy occurs or is suspected.

It is not known whether Axinix passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during treatment and for at least one week after the final dose. Consult a physician before breastfeeding.

Axinix requires close specialist oncology monitoring throughout treatment. It is not intended for use as a general-practice medication.

Hypertension

Hypertension, including hypertensive crisis, is common with Axinix. Blood pressure should be well-controlled before starting treatment and monitored regularly thereafter; treatment may require temporary interruption, dose reduction, or antihypertensive therapy.

Arterial and Venous Thromboembolic Events

Arterial events (e.g. myocardial infarction, stroke) and venous events (e.g. deep vein thrombosis, pulmonary embolism) have occurred. Axinix should be permanently discontinued in patients who develop a serious arterial thromboembolic event.

Hemorrhage

Axinix has not been studied in patients with untreated brain metastases, recent active gastrointestinal bleeding, or hemoptysis, and should be used with caution or avoided in these settings. Discontinue permanently for severe or life-threatening hemorrhage.

Gastrointestinal Perforation and Fistula

Gastrointestinal perforation or fistula formation has been reported. Monitor for symptoms and manage promptly.

Hepatotoxicity

Elevated liver enzymes can occur and are more pronounced when Axinix is given in combination regimens with checkpoint inhibitors. Liver function should be monitored regularly, especially in the first weeks of combination treatment; severe hepatotoxicity may require corticosteroid therapy and treatment interruption.

Hypothyroidism

Thyroid function (TSH) should be monitored periodically before and during treatment; thyroid hormone replacement should be initiated as needed.

Proteinuria

Urine protein should be monitored periodically. Treatment should be withheld and the dose reduced for severe proteinuria.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

RPLS is a rare but serious neurological condition. Seek urgent medical attention for severe headache, seizures, lethargy, confusion, or visual disturbances; Axinix should be permanently discontinued if RPLS is confirmed.

Impaired Wound Healing

Axinix can impair wound healing. Treatment should be withheld for at least 2 days before elective surgery and only resumed after adequate wound healing has been confirmed.

There is no specific antidote for Axinix overdose. In case of a suspected overdose, seek immediate medical attention or contact emergency services / a poison control center. Management is supportive, with close monitoring of blood pressure and other vital signs, along with general supportive measures as directed by medical staff.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No initial dose adjustment is required for mild-to-moderate renal impairment. Use with caution in severe renal impairment, as data are limited.

Hepatic Impairment

Reduce the starting dose by approximately half in moderate impairment (Child-Pugh B); use in severe impairment (Child-Pugh C) is not recommended (see Dosage and Administration).

Elderly

No overall differences in effectiveness have been observed between elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out; monitor closely.

Pediatric Use

Safety and efficacy of Axinix in pediatric patients have not been established.

Axinix is generally continued for as long as the patient experiences clinical benefit (disease control) and adverse effects remain tolerable or manageable. The oncologist will periodically reassess response using imaging and clinical evaluation, and treatment is stopped for disease progression or unacceptable toxicity.

Axitinib belongs to the VEGFR-selective tyrosine kinase inhibitor (TKI) class of antineoplastic, angiogenesis-inhibiting agents.

Axitinib selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, blocking VEGF-driven angiogenesis. This deprives tumors of the new blood vessel formation needed for growth and spread, slowing progression of renal cell carcinoma.

The safety and efficacy of Axinix in pediatric patients have not been established. Axinix is not recommended for use in children.